Similar articles

• Dynamics of the pool of infected resting CD4 HLA-DR- T lymphocytes in patients who started a triple class five-drug antiretroviral regimen during primary HIV-1 infection.

  Sankatsing SU, van Praag RM, van Rij RP, Rientsma R, Jurriaans S, Lange JM, Prins JM, Schuitemaker H. Sankatsing SU, et al. Antivir Ther. 2003 Apr;8(2):137-42. Antivir Ther. 2003. PMID: 12741626
• Effect of antiretroviral therapy on plasma HIV RNA.

  Saag MS. Saag MS. J Biol Regul Homeost Agents. 1995 Jul-Sep;9(3):105-6. J Biol Regul Homeost Agents. 1995. PMID: 8782017 Review. No abstract available.
• Immune control of HIV-1 after early treatment of acute infection.

  Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RL, Robbins GK, D'Aquila RT, Goulder PJ, Walker BD. Rosenberg ES, et al. Nature. 2000 Sep 28;407(6803):523-6. doi: 10.1038/35035103. Nature. 2000. PMID: 11029005 Clinical Trial.
• Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia.

  Zaunders JJ, Cunningham PH, Kelleher AD, Kaufmann GR, Jaramillo AB, Wright R, Smith D, Grey P, Vizzard J, Carr A, Cooper DA. Zaunders JJ, et al. J Infect Dis. 1999 Aug;180(2):320-9. doi: 10.1086/314880. J Infect Dis. 1999. PMID: 10395845 Clinical Trial.
• Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward.

  Abbas UL, Mellors JW. Abbas UL, et al. Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13377-8. doi: 10.1073/pnas.212518999. Epub 2002 Oct 7. Proc Natl Acad Sci U S A. 2002. PMID: 12370421 Free PMC article. Review. No abstract available.